JHU-NUS Center for Research on CAMs(Planning Grant)

JHU-NUS CAM 研究中心（规划资助）

• 批准号: 6738637
• 负责人: PAUL S LIETMAN
• 金额: $ 13.87万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-15 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6738637
• 关键词: alternative medicine; antineoplastics; biomarker; health science research support; international cooperation; medicinal plants; southeast Asia

DESCRIPTION (provided by applicant): This proposal is a response to an RFA (AT-03-002) from the National Center for Complementary and Alternative Medicine (NCCAM) entitled "PLANNING GRANT FOR INTERNATIONAL CENTERS FOR RESEARCH ON COMPLEMENTARY AND ALTERNATIVE MEDICINE (PICRC)". The unique position of Johns Hopkins in Singapore and the attributes of Singapore itself make Singapore an excellent site for an NIH NCCAM regional International Center for Research on Complementary and Alternative Medicine (ICRC). The proposal is from The Johns Hopkins University School of Medicine in Baltimore and the National University of Singapore and will include collaboration with units in China as well. The Principal Investigator, Paul S. Lietman is a physician-scientist with considerable experience in the organization and leadership of research entities that are focused on clinical research, clinical pharmacology, and the building of an international research unit in Singapore. He and the Singapore Co-Investigator, Eu Leong YONG, also a physician-scientist, have worked closely to assemble a team in Singapore (with JHU collaborators) that could significantly enhance the infrastructure of an embryonic CAM research capacity in Singapore and Southeast Asia. The goal of this proposal will be on the creation of a full-fledged grant application for an International Center for CAM Research (ICRC) in Singapore that includes 3 projects and a core facility. The proposal focuses on several of the most highly significant areas of CAM research, namely: 1. The standardization of TCM products to be studied by plant genomic and biochemical means, the reliable sourcing of herbs and edible plants, and the formulation and manufacturing of products following GMP 2. The development and validation of biomarkers that will facilitate the rigorous study of potentially bioactive herbal and food substances in humans 3. The elucidation of the cancer chemopreventative properties of edible tropical plants 4. The careful and rigorous conduct of clinical research that is essential to prove or disprove the biologic effects of potential therapeutic agents in humans and the clinical studies of interactions of TCMs with commonly prescribed chemotherapeutic agents.

描述(由申请人提供)：本提案是对国家补充和替代医学中心(NCCAM)题为“国际补充和替代医学研究中心(PICRC)规划资助”的RFA(AT-03-002)的回应。 约翰霍普金斯大学在新加坡的独特位置和新加坡本身的特点使新加坡成为NIH NCCAM地区补充和替代医学研究国际中心(ICRC)的绝佳地点。该提案来自巴尔的摩的约翰·霍普金斯大学医学院和新加坡国立大学，还将包括与中国的单位合作。 首席研究员Paul S.Lietman是一名内科科学家，在组织和领导专注于临床研究、临床药理学和在新加坡建立国际研究单位的研究实体方面拥有丰富的经验。他和新加坡联合调查员梁勇(Eu Leong Yong)也是一名医生和科学家，他们密切合作，在新加坡组建了一个团队(与JHU的合作者)，可以显著增强新加坡和东南亚早期CAM研究能力的基础设施。 这项提议的目标将是为新加坡的国际计算机辅助制造研究中心(ICRC)创建一个成熟的赠款申请，该中心包括3个项目和一个核心设施。该提案侧重于CAM研究的几个最重要的领域，即： 1.利用植物基因组和生物化学手段研究中药产品的标准化，中草药和食用植物的可靠来源，以及符合GMP的产品的配方和制造 2.开发和验证生物标志物，以促进对人类潜在生物活性草药和食品物质的严格研究 3.热带食用植物抗癌化学预防特性的阐明 4.仔细和严格地进行临床研究，这对于证明或反驳潜在的人类治疗药物的生物效应是必不可少的，以及对中药与常用处方化疗药物相互作用的临床研究。